Literature DB >> 29781819

Staging of Bone and Soft-tissue Sarcomas.

Robert J Steffner1, Eugene S Jang.   

Abstract

The purpose of staging in orthopaedic oncology is to provide a framework for classifying tumors based on their risk of local recurrence and distant metastasis to guide treatment decisions. Two separate systems are commonly used to categorize bone and soft-tissue sarcomas. The Musculoskeletal Tumor Society system for bone sarcomas and the Enneking system for soft-tissue sarcomas are the original staging systems developed by orthopaedic surgeons. The American Joint Committee on Cancer staging systems for bone and soft-tissue sarcomas are periodically updated based on new data, and they are currently on their eighth edition.

Entities:  

Mesh:

Year:  2018        PMID: 29781819     DOI: 10.5435/JAAOS-D-17-00055

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  14 in total

1.  Letter to the editor: "How to confront the high prevalence of pulmonary micro nodules (PMNs) in osteosarcoma patients?"

Authors:  Ping Yu; Zhengliang Zhang
Journal:  Int Orthop       Date:  2022-09-26       Impact factor: 3.479

Review 2.  Secondary Malignancy in Giant Cell Tumor: A Single-Center Study.

Authors:  Min Wook Joo; Yong-Suk Lee; Hong Sik Park; Yang-Guk Chung; Chiyoung Yoon
Journal:  Curr Oncol       Date:  2022-06-02       Impact factor: 3.109

3.  Long non-coding RNA ELF3-antisense RNA 1 promotes osteosarcoma cell proliferation by upregulating Kruppel-like factor 12 potentially via methylation of the microRNA-205 gene.

Authors:  Jianmin Yuan; Jianhui Kang; Min Yang
Journal:  Oncol Lett       Date:  2020-01-16       Impact factor: 2.967

4.  MicroRNA-221 promotes cisplatin resistance in osteosarcoma cells by targeting PPP2R2A.

Authors:  Wen-Chao Yu; Hui-Hao Chen; Yan-Yan Qu; Chun-Wei Xu; Chen Yang; Yan Liu
Journal:  Biosci Rep       Date:  2019-07-10       Impact factor: 3.840

5.  Changes in Soft-Tissue Sarcoma Treatment Patterns over Time: A Population-Based Study in a Country with Universal and Centralized Healthcare.

Authors:  Anthony Bozzo; Hsien Seow; Gregory Pond; Michelle Ghert
Journal:  Sarcoma       Date:  2019-09-16

6.  Distinction between benign and malignant soft tissue tumors based on an ultrasonographic evaluation of vascularity and elasticity.

Authors:  Shusa Ohshika; Tatsuro Saruga; Tetsuya Ogawa; Hiroya Ono; Yasuyuki Ishibashi
Journal:  Oncol Lett       Date:  2021-02-10       Impact factor: 2.967

7.  Prognostic Implications of the Complement Protein C1Q and Its Correlation with Immune Infiltrates in Osteosarcoma.

Authors:  Hanji Huang; Manli Tan; Li Zheng; Guohua Yan; Kanglu Li; Dejie Lu; Xiaofei Cui; Si He; Danqing Lei; Bo Zhu; Jinmin Zhao
Journal:  Onco Targets Ther       Date:  2021-03-05       Impact factor: 4.147

8.  Biological reconstruction in the treatment of extremity sarcoma in femur, tibia, and humerus.

Authors:  Weitao Yao; Qiqing Cai; Jiaqiang Wang; Peng Zhang; Xin Wang; Xinhui Du; Xiaohui Niu
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

9.  Outcomes of comprehensive treatment for primary osteosarcoma.

Authors:  Kazuhiko Hashimoto; Shunji Nishimura; Naohiro Oka; Masao Akagi
Journal:  SAGE Open Med       Date:  2020-05-20

Review 10.  Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma.

Authors:  Shenglong Li
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.